Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab consolidation in locally advanced ESCC
NCT04286958Phase 2Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04286958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04286958.